Clinical Trials · NCT01272973
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 96
- Start date
- Jan 2011
- Locations
- 1 site, Germany
- Primary endpoint
- Frequency of adverse events (AEs)